Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.41 |
| ▸ | ACACA | Q13085 | 4/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2213365 | 1.00 | ACACB (0.41) | ACACBACACAGPR119HRH3RAB9A | |
| SCHEMBL2215213 | 0.96 | GPR119 (0.40) | ACACBACACAGPR119HRH3RAB9A | |
| SCHEMBL2215222 | 0.96 | GPR119 (0.40) | ACACBACACAGPR119HRH3RAB9A | |
| SCHEMBL2214821 | 0.90 | ACACB (0.43) | ACACBACACAGPR119RAB9ANPC1 | |
| SCHEMBL2219354 | 0.90 | ACACB (0.46) | ACACBACACAGPR119RAB9ANPC1 | |
| SCHEMBL2217076 | 0.89 | GPR119 (0.40) | ACACBACACAGPR119HRH3RAB9A | |
| SCHEMBL2217078 | 0.89 | GPR119 (0.40) | ACACBACACAGPR119HRH3RAB9A | |
| SCHEMBL2217772 | 0.89 | ACACB (0.40) | ACACBACACAGPR119HRH3 | |
| SCHEMBL2217895 | 0.89 | ACACB (0.44) | ACACBACACAGPR119HRH3RAB9A | |
| SCHEMBL13536322 | 0.89 | ACACB (0.42) | ACACBACACAGPR119RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | ACACB 2654/4885ACACA 2114/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.